Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
CRVS's Cash-to-Debt is ranked higher than
66% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. CRVS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CRVS' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
CRVS's Interest Coverage is ranked higher than
56% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CRVS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CRVS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 18.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -50.04
CRVS's ROE % is ranked lower than
56% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. CRVS: -50.04 )
Ranked among companies with meaningful ROE % only.
CRVS' s ROE % Range Over the Past 10 Years
Min: -71.53  Med: -61.34 Max: -50.04
Current: -50.04
-71.53
-50.04
ROA % -45.64
CRVS's ROA % is ranked lower than
59% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. CRVS: -45.64 )
Ranked among companies with meaningful ROA % only.
CRVS' s ROA % Range Over the Past 10 Years
Min: -56.47  Med: -47.39 Max: -30.49
Current: -45.64
-56.47
-30.49
ROC (Joel Greenblatt) % -1949.31
CRVS's ROC (Joel Greenblatt) % is ranked lower than
71% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. CRVS: -1949.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1949.31  Med: -1492.68 Max: -1452.03
Current: -1949.31
-1949.31
-1452.03
GuruFocus has detected 2 Warning Signs with Corvus Pharmaceuticals Inc CRVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRVS's 30-Y Financials

Financials (Next Earnings Date: 2018-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

CRVS Guru Trades in Q2 2017

Jim Simons 137,100 sh (+137.20%)
Steven Cohen 232,383 sh (-43.08%)
» More
Q3 2017

CRVS Guru Trades in Q3 2017

Jim Simons 194,300 sh (+41.72%)
Steven Cohen 195,034 sh (-16.07%)
» More
Q4 2017

CRVS Guru Trades in Q4 2017

Jim Simons 234,200 sh (+20.54%)
Steven Cohen Sold Out
» More
Q1 2018

CRVS Guru Trades in Q1 2018

Jim Simons 426,700 sh (+82.19%)
» More
» Details

Insider Trades

Latest Guru Trades with CRVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Corvus Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:XXII, NAS:NK, BOM:512529, TSE:4571, TSX:ZYME, SZSE:000004, XKRX:046210, NAS:ABUS, LSE:MPH, TSE:4564, ROCO:4128, NAS:SVRA, NAS:BSTC, NAS:MBIO, NAS:MNKD, AMEX:BTX, NAS:COOL, ROCO:6586, NAS:TORC, NAS:NLNK » details
Traded in other countries:C17.Germany,
Headquarter Location:USA
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The company is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The company is developing products that either block immune checkpoints and/or reprogram immune cells. The group competes with universities and other research institutions.

Top Ranked Articles about Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum
Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update
Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference
Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

Ratios

vs
industry
vs
history
PB Ratio 1.97
CRVS's PB Ratio is ranked higher than
72% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CRVS: 1.97 )
Ranked among companies with meaningful PB Ratio only.
CRVS' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.5
Current: 1.97
0
3.5
EV-to-EBIT -4.23
CRVS's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. CRVS: -4.23 )
Ranked among companies with meaningful EV-to-EBIT only.
CRVS' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.98  Med: 0 Max: 0
Current: -4.23
-8.98
0
EV-to-EBITDA -4.29
CRVS's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. CRVS: -4.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.14  Med: 0 Max: 0
Current: -4.29
-9.14
0
Current Ratio 13.69
CRVS's Current Ratio is ranked higher than
80% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. CRVS: 13.69 )
Ranked among companies with meaningful Current Ratio only.
CRVS' s Current Ratio Range Over the Past 10 Years
Min: 10.11  Med: 22.89 Max: 111.05
Current: 13.69
10.11
111.05
Quick Ratio 13.69
CRVS's Quick Ratio is ranked higher than
81% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. CRVS: 13.69 )
Ranked among companies with meaningful Quick Ratio only.
CRVS' s Quick Ratio Range Over the Past 10 Years
Min: 10.11  Med: 22.89 Max: 111.05
Current: 13.69
10.11
111.05

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.05
CRVS's Price-to-Net-Cash is ranked higher than
86% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. CRVS: 2.05 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRVS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.83  Med: 2.49 Max: 3.84
Current: 2.05
1.83
3.84
Price-to-Net-Current-Asset-Value 2.03
CRVS's Price-to-Net-Current-Asset-Value is ranked higher than
85% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CRVS: 2.03 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRVS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.82  Med: 2.47 Max: 3.8
Current: 2.03
1.82
3.8
Price-to-Tangible-Book 1.98
CRVS's Price-to-Tangible-Book is ranked higher than
79% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CRVS: 1.98 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.77  Med: 2.41 Max: 3.68
Current: 1.98
1.77
3.68
Earnings Yield (Greenblatt) % -23.58
CRVS's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. CRVS: -23.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -555.6  Med: 0 Max: 0
Current: -23.58
-555.6
0

More Statistics

EPS (TTM) $ -2.56
Volatility80.03%
52-Week Range $7.42 - 17.64
Shares Outstanding (Mil)29.19

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $)
EBIT (Mil $) -76,641 -115,000 -94,375
EBITDA (Mil $) -76,054 -114,539 -93,539
EPS ($) -2.76 -2.69 -1.99
EPS without NRI ($) -2.76 -2.69 -1.99
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}